Penetrium Bioscience페니트리움바이오
187660 · KOSDAQ · ₩187660 · 페니트리움바이오
₩6,170▼ ₩490 (7.36%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩9.3B | ₩9.7B | ₩14B | ₩15B | ₩14B |
| Cost of sales | ₩9.2B | ₩9.6B | ₩11B | ₩11B | ₩6.7B |
| Gross profit | ₩34M | ₩101M | ₩3.2B | ₩4.4B | ₩7.3B |
| Operating income | −₩7.4B | −₩16B | −₩1.9B | ₩517M | ₩2.4B |
| Net income | −₩15B | −₩22B | −₩3.8B | ₩1.1B | ₩2.1B |
| Net income to shareholders | −₩15B | −₩22B | −₩3.8B | ₩1.1B | ₩2.1B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩33B | ₩28B | ₩45B | ₩47B | ₩39B |
| Current assets | ₩9.3B | ₩11B | ₩26B | ₩40B | ₩35B |
| Cash and equivalents | ₩4.8B | ₩5.8B | ₩3.3B | ₩3.1B | ₩5.2B |
| Total liabilities | ₩11B | ₩22B | ₩16B | ₩14B | ₩4.2B |
| Current liabilities | ₩10B | ₩21B | ₩15B | ₩14B | ₩3.8B |
| Borrowings | ₩5B | ₩8.2B | — | — | — |
| Total equity | ₩22B | ₩6.4B | ₩29B | ₩33B | ₩34B |
| Shareholders' equity | ₩22B | ₩6.4B | ₩29B | ₩33B | ₩34B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩4.5B | −₩14B | −₩1.3B | ₩1.9B | ₩1.3B |
| Capital spending | ₩748M | ₩54M | ₩141M | ₩401M | ₩1.1B |
| Free cash flow | −₩5.2B | −₩14B | −₩1.5B | ₩1.5B | ₩194M |
Consolidated where available. Amounts in won.
Also known as: Penetrium Bioscience / 페니트리움바이오 / 187660 / KRX:187660
Source: KRX statistical information